We conclude that the expression of Nrf2, in conjunction with TrxR expression, is involved in imatinib resistance of CML and the Nrf2-TrxR axis could be used as a therapy target for imatinib-resistant CML. This evidence concerns the gene NFE2L2 and chronic myelogenous leukemia, BCR-ABL1 positive.